Close

BioCryst (BCRX) Receives Prelim. Comment Letter from FDA for Peramivir

Go back to BioCryst (BCRX) Receives Prelim. Comment Letter from FDA for Peramivir
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) Delayed: 5.07 +0.07 (1.40%)
Previous Close $5.00    52 Week High $10.98 
Open $5.00    52 Week Low $1.63 
Day High $5.18    P/E N/A 
Day Low $4.89    EPS $-0.68 
Volume 4,350,738